PMID- 33769463
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20221202
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Print)
IS  - 0003-9985 (Linking)
VI  - 145
IP  - 12
DP  - 2021 Dec 1
TI  - Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group 
      Trial for Newly Diagnosed Metastatic Ewing Sarcoma.
PG  - 1564-1568
LID - 10.5858/arpa.2020-0671-OA [doi]
AB  - CONTEXT.-: Molecular diagnostics play an increasing role in the diagnosis of 
      Ewing sarcoma. The type of molecular testing used in clinical practice has been 
      poorly described. OBJECTIVE.-: To describe patterns of translocation testing for 
      newly diagnosed Ewing sarcoma. DESIGN.-: Children's Oncology Group (COG) trial 
      AEWS1221 was a phase III randomized trial enrolling patients with newly diagnosed 
      metastatic Ewing sarcoma from 2014 to 2019. Patients were required to have a 
      histologic diagnosis of Ewing sarcoma, but translocation testing was not 
      required. Sites provided types and results of any molecular diagnostics 
      performed. RESULTS.-: Data from 305 enrolled patients were available. The most 
      common type of molecular testing was fluorescence in situ hybridization (FISH) 
      performed on the primary tumor (236 of 305 patients; 77.4%), with positive 
      testing for an EWSR1 or FUS translocation in 211 (89.4%). Reverse 
      transcription-polymerase chain reaction (RT-PCR) on the primary tumor was 
      performed in 61 of 305 patients (20%), with positive results in 48 of 61 patients 
      (78.7%). Next-generation sequencing was reported in 7 patients for the primary 
      tumor and in 3 patients for metastatic sites. For all types of testing on either 
      primary or metastatic tumor, 16 of 305 patients (5.2%) had no reported 
      translocation testing. When evaluating all results from all testing, 44 of 305 
      patients (14.4%) lacked documentation of an abnormality consistent with a 
      molecular diagnosis of Ewing sarcoma. CONCLUSIONS.-: COG sites enrolling in a 
      Ewing sarcoma trial have high rates of testing by FISH or PCR. A small proportion 
      of patients have no translocation testing on either primary or metastatic sites. 
      Next-generation sequencing techniques are not yet commonly used in this context.
FAU - DuBois, Steven G
AU  - DuBois SG
AD  - From Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard 
      Medical School, Boston, Massachusetts (DuBois, Crompton, Janeway).
FAU - Krailo, Mark D
AU  - Krailo MD
AD  - Children's Oncology Group Statistics and Data Center, Monrovia, California 
      (Krailo, Buxton).
FAU - Buxton, Allen
AU  - Buxton A
AD  - Children's Oncology Group Statistics and Data Center, Monrovia, California 
      (Krailo, Buxton).
FAU - Lessnick, Stephen L
AU  - Lessnick SL
AD  - Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research 
      Institute, Nationwide Children's Hospital, and the Division of Pediatric 
      Heme/Onc/BMT, the Ohio State University College of Medicine, Columbus (Lessnick).
FAU - Teot, Lisa A
AU  - Teot LA
AD  - The Department of Pathology, Boston Children's Hospital, Harvard Medical School, 
      Boston, Massachusetts (Teot).
FAU - Rakheja, Dinesh
AU  - Rakheja D
AD  - The Department of Pathology, University of Texas Southwestern Medical Center, 
      Dallas (Rakheja).
FAU - Crompton, Brian D
AU  - Crompton BD
AD  - From Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard 
      Medical School, Boston, Massachusetts (DuBois, Crompton, Janeway).
FAU - Janeway, Katherine A
AU  - Janeway KA
AD  - From Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard 
      Medical School, Boston, Massachusetts (DuBois, Crompton, Janeway).
FAU - Gorlick, Richard G
AU  - Gorlick RG
AD  - The Department of Pediatrics, MD Anderson Cancer Center, Houston, Texas 
      (Gorlick).
FAU - Glade-Bender, Julia
AU  - Glade-Bender J
AD  - The Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, 
      New York (Glade-Bender).
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - U10 CA180886/CA/NCI NIH HHS/United States
GR  - U10 CA180899/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RNA-Binding Protein EWS)
SB  - IM
MH  - *Bone Neoplasms/diagnosis/genetics
MH  - Child
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Neuroectodermal Tumors, Primitive, Peripheral
MH  - Oncogene Proteins, Fusion/genetics
MH  - Pathology, Molecular
MH  - RNA-Binding Protein EWS/genetics
MH  - *Sarcoma, Ewing/diagnosis/genetics
MH  - Translocation, Genetic
PMC - PMC9048754
MID - NIHMS1792780
EDAT- 2021/03/27 06:00
MHDA- 2022/01/18 06:00
PMCR- 2022/12/01
CRDT- 2021/03/26 12:53
PHST- 2020/12/30 00:00 [accepted]
PHST- 2021/03/27 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/03/26 12:53 [entrez]
PHST- 2022/12/01 00:00 [pmc-release]
AID - 463212 [pii]
AID - 10.5858/arpa.2020-0671-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2021 Dec 1;145(12):1564-1568. doi: 
      10.5858/arpa.2020-0671-OA.